The pleiotropic nature of IL-10 has made translating the potential benefit of IL-10-modulating therapies into the clinic difficult; however, strategies designed to focus IL-10 expression onto antigen-specific T cells, including SIT for allergic and autoimmune diseases, have shown promising early results. Here, IL10 is linked to autoimmune disease.